Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

307
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
307
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

1.3K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
1.3K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.2K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.2K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

110
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
110
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

819
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
819

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for clinical implementation.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V·2026
Same author

Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis.

Nature genetics·2026
Same author

HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Hepatoprotective Effects of Fused Pyridine Derivatives: Regulation of the TGF-β/Smad, miR-21/Smad7, and PPARγ Pathways in Carbon Tetrachloride-Induced Liver Fibrosis.

Drug design, development and therapy·2026
Same author

Adiponectin modulates the diurnal hepatic transcriptome and energy metabolism in male mice.

Endocrine connections·2026
Same author

The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress.

Pharmacogenomics·2026

Related Experiment Video

Updated: Jul 27, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Pharmacogenomics in practice: a review and implementation guide.

Danya Kabbani1, Reem Akika1, Ahmed Wahid2

  • 1Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

Frontiers in Pharmacology
|June 5, 2023
PubMed
Summary

Pharmacogenomics (PGx) implementation in hospitals involves evaluating evidence, selecting actionable drug-gene pairs, and choosing testing strategies. Successful integration requires collaboration among leadership, pharmacy, IT, and healthcare providers for improved patient care.

Keywords:
guidelinesimplementationpharmacogeneticspharmacogenomicspractice

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

3.7K

Related Experiment Videos

Last Updated: Jul 27, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

3.7K

Area of Science:

  • Pharmacogenomics
  • Clinical implementation
  • Personalized medicine

Background:

  • Pharmacogenomics (PGx) studies genetic variations influencing drug response.
  • Implementing PGx into routine clinical practice can enhance treatment outcomes.
  • Standardized approaches are needed for effective PGx integration in healthcare settings.

Purpose of the Study:

  • To propose a structured approach for initiating clinical pharmacogenomics in hospitals.
  • To outline key considerations for evidence evaluation, test selection, and result interpretation.
  • To identify essential stakeholders and strategies for successful PGx implementation.

Main Methods:

  • Evaluating PGx evidence from sources like PharmGKB and CPIC.
  • Identifying actionable drug-gene pairs based on expert consensus and regulatory guidance (FDA, EMA).
  • Differentiating testing strategies (reactive vs. preemptive, candidate vs. panel) and planning for EHR integration.

Main Results:

  • A systematic framework for clinical PGx implementation is presented.
  • Key steps include evidence assessment, drug-gene pair selection, genotyping strategy, and result reporting.
  • Successful implementation relies on multi-stakeholder collaboration and leadership support.

Conclusions:

  • Clinical pharmacogenomics implementation requires a phased approach involving evidence review, strategic testing, and stakeholder engagement.
  • Education for healthcare providers and patients, alongside reimbursement advocacy, is crucial for advancing PGx practice.
  • Available resources and successful initiatives can guide further PGx program development.